Role of Mecp2 in experience-dependent epigenetic programming

Genes

Volumn 6, Issue 1, 2015, Pages 60-86

  Zimmermann, Christoph A ^a   Hoffmann, Anke ^a   Raabe, Florian ^a   Spengler, Dietmar ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Avp; Crh; Early life stress; Epigenetic programming; HPA axis; Mecp2; Pomc

Indexed keywords

DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE 3L; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; METHYL CPG BINDING PROTEIN 2; UNCLASSIFIED DRUG;

AVP GENE; CLINICAL FEATURE; CPG ISLAND; CRH GENE; DEPRESSION; DNA BINDING; DNA MODIFICATION; DRUG DEPENDENCE; EARLY LIFE STRESS; EPIGENETICS; GENE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE TARGETING; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LEARNING; MECP2 GENE; MEMORY; MOOD DISORDER; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; POMC GENE; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RETT SYNDROME; REVIEW; TRANSCRIPTION REGULATION;

MUS;

EID: 84924295961     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes6010060     Document Type: Review

References (128)

1. Waddington, C.H. The Strategy of the Genes. A Discussion of Some Aspects of Theoretical Biology; Routledge: London, UK, 2014.
2. Russo, V.E.A.; Martienssen, R.A.; Riggs, A.D. Epigenetic Mechanisms of Gene Regulation; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 1996; Volume 32.
3. Allis, C.D.; Jenuwein, T.; Reinberg, D. Epigenetics; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2007.
4. Ausió, J.; de Paz, A.M.; Esteller, M. MeCP2: The long trip from a chromatin protein to neurological disorders. Trends Mol. Med. 2014, 20, 487–498.
5. Chahrour, M.; Zoghbi, H.Y. The story of rett syndrome: From clinic to neurobiology. Neuron 2007, 56, 422–437.
6. Murgatroyd, C.; Spengler, D. Genetic variation in the epigenetic machinery and mental health. Curr. Psychiatry Rep. 2012, 14, 138–149.
7. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16, 6–21.
8. Zhang, T.-Y.; Meaney, M.J. Epigenetics and the environmental regulation of the genome and its function. Annu. Rev. Psychol. 2010, 61, 439–466.
9. Murgatroyd, C.; Wu, Y.; Bockmühl, Y.; Spengler, D. Genes learn from stress: How infantile trauma programs us for depression. Epigenetics 2010, 5, 194–199.
10. Hoffmann, A.; Spengler, D. DNA memories of early social life. Neuroscience 2014, 264, 64–75.
11. Goldberg, A.D.; Allis, C.D.; Bernstein, E. Epigenetics: A landscape takes shape. Cell 2007, 128, 635–638.
12. Eccleston, A.; DeWitt, N.; Gunter, C.; Marte, B.; Nath, D. Insight: Introduction Epigenetics. Nature 2007, 447, 395.
13. Tollefsbol, T.O. Handbook of Epigenetics: The New Molecular and Medical Genetics; 1 edition; Academic Press: London, UK, 2010.
14. Armstrong, L. Epigenetics; Garland Science: New York, NY, USA, 2013.
15. Lister, R.; Mukamel, E.A.; Nery, J.R.; Urich, M.; Puddifoot, C.A.; Johnson, N.D.; Lucero, J.; Huang, Y.; Dwork, A.J.; Schultz, M.D.; et al. Global epigenomic reconfiguration during mammalian brain development. Science 2013, 341, doi:10.1126/science.1237905.
16. Ooi, S.K.T.; O’Donnell, A.H.; Bestor, T.H. Mammalian cytosine methylation at a glance. J. Cell Sci. 2009, 122, 2787–2791.
17. Kareta, M.S.; Botello, Z.M.; Ennis, J.J.; Chou, C.; Chédin, F. Reconstitution and mechanism of the stimulation of de Novo methylation by human DNMT3L. J. Biol. Chem. 2006, 281, 25893–25902.
18. Saxonov, S.; Berg, P.; Brutlag, D.L. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl. Acad. Sci. USA 2006, 103, 1412–1417.
19. Gibney, E.R.; Nolan, C.M. Epigenetics and gene expression. Heredity 2010, 105, 4–13.
20. Bell, J.T.; Pai, A.A.; Pickrell, J.K.; Gaffney, D.J.; Pique-Regi, R.; Degner, J.F.; Gilad, Y.; Pritchard, J.K. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 2011, 12, R10.
21. Thurman, R.E.; Rynes, E.; Humbert, R.; Vierstra, J.; Maurano, M.T.; Haugen, E.; Sheffield, N.C.; Stergachis, A.B.; Wang, H.; Vernot, B.; et al. The accessible chromatin landscape of the human genome. Nature 2012, 489, 75–82.
22. Weber, M.; Hellmann, I.; Stadler, M.B.; Ramos, L.; Pääbo, S.; Rebhan, M.; Schübeler, D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 2007, 39, 457–466.
23. Zemach, A.; McDaniel, I.E.; Silva, P.; Zilberman, D. Genome-Wide Evolutionary Analysis of Eukaryotic DNA Methylation. Science 2010, 328, 916–919.
24. Feng, S.; Cokus, S.J.; Zhang, X.; Chen, P.-Y.; Bostick, M.; Goll, M.G.; Hetzel, J.; Jain, J.; Strauss, S.H.; Halpern, M.E.; et al. Conservation and divergence of methylation patterning in plants and animals. Proc. Natl. Acad. Sci. USA 2010, 107, 8689–8694.
25. Maunakea, A.K.; Nagarajan, R.P.; Bilenky, M.; Ballinger, T.J.; D’Souza, C.; Fouse, S.D.; Johnson, B.E.; Hong, C.; Nielsen, C.; Zhao, Y.; et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010, 466, 253–257.
26. Gibbs, J.R.; van der Brug, M.P.; Hernandez, D.G.; Traynor, B.J.; Nalls, M.A.; Lai, S.-L.; Arepalli, S.; Dillman, A.; Rafferty, I.P.; Troncoso, J.; et al. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010, 6, e1000952.
27. Gutierrez-Arcelus, M.; Lappalainen, T.; Montgomery, S.B.; Buil, A.; Ongen, H.; Yurovsky, A.; Bryois, J.; Giger, T.; Romano, L.; Planchon, A.; et al. Passive and active DNA methylation and the interplay with genetic variation in gene regulation. eLife 2013, 2, e00523.
28. Wu, H.; Zhang, Y. Reversing DNA methylation: Mechanisms, genomics, and Biological functions. Cell 2014, 156, 45–68.
29. Tahiliani, M.; Koh, K.P.; Shen, Y.; Pastor, W.A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L.M.; Liu, D.R.; Aravind, L.; et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324, 930–935.
30. Ito, S.; D’Alessio, A.C.; Taranova, O.V.; Hong, K.; Sowers, L.C.; Zhang, Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466, 1129–1133.
31. Ito, S.; Shen, L.; Dai, Q.; Wu, S.C.; Collins, L.B.; Swenberg, J.A.; He, C.; Zhang, Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333, 1300–1303.
32. He, Y.-F.; Li, B.-Z.; Li, Z.; Liu, P.; Wang, Y.; Tang, Q.; Ding, J.; Jia, Y.; Chen, Z.; Li, L.; et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333, 1303–1307.
33. Cortellino, S.; Xu, J.; Sannai, M.; Moore, R.; Caretti, E.; Cigliano, A.; le Coz, M.; Devarajan, K.; Wessels, A.; Soprano, D.; et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011, 146, 67–79.
34. Guo, J.U.; Su, Y.; Zhong, C.; Ming, G.; Song, H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle 2011, 10, 2662–2668.
35. Maiti, A.; Drohat, A.C. Thymine DNA Glycosylase Can Rapidly Excise 5-formylcytosine and 5-carboxylcytosine potential implications for active demethylation of CpG sites. J. Biol. Chem. 2011, 286, 35334–35338.
36. Spruijt, C.G.; Gnerlich, F.; Smits, A.H.; Pfaffeneder, T.; Jansen, P.W.T.C.; Bauer, C.; Münzel, M.; Wagner, M.; Müller, M.; Khan, F.; et al. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 2013, 152, 1146–1159.
37. Li, B.; Carey, M.; Workman, J.L. The role of chromatin during transcription. Cell 2007, 128, 707–719.
38. Misteli, T. Beyond the sequence: Cellular organization of genome function. Cell 2007, 128, 787–800.
39. Cairns, B.R. Chromatin remodeling: Insights and intrigue from single-molecule studies. Nat. Struct. Mol. Biol. 2007, 14, 989–996.
40. Berger, S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447, 407–412.
41. Bernstein, B.E.; Meissner, A.; Lander, E.S. The mammalian epigenome. Cell 2007, 128, 669–681.
42. Hendrich, B.; Bird, A. Identification and characterization of a family of mammalian Methyl-CpG binding proteins. Mol. Cell. Biol. 1998, 18, 6538–6547.
43. Dani, V.S.; Chang, Q.; Maffei, A.; Turrigiano, G.G.; Jaenisch, R.; Nelson, S.B. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett Syndrome. Proc. Natl. Acad. Sci. USA 2005, 102, 12560–12565.
44. Chao, H.-T.; Zoghbi, H.Y.; Rosenmund, C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 2007, 56, 58–65.
45. Tropea, D.; Giacometti, E.; Wilson, N.R.; Beard, C.; McCurry, C.; Fu, D.D.; Flannery, R.; Jaenisch, R.; Sur, M. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl. Acad. Sci. USA 2009, 106, 2029–2034.
46. Adkins, N.L.; Georgel, P.T. MeCP2: structure and function. Biochem. Cell. Biol. 2010, 89, 1–11.
47. Pelka, G.J.; Watson, C.M.; Christodoulou, J.; Tam, P.P.L. Distinct expression profiles of Mecp2 transcripts with different lengths of 3'UTR in the brain and visceral organs during mouse development. Genomics 2005, 85, 441–452.
48. Shahbazian, M.D.; Antalffy, B.; Armstrong, D.L.; Zoghbi, H.Y. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum. Mol. Genet. 2002, 11, 115–124.
49. Na, E.S.; Monteggia, L.M. The role of MeCP2 in CNS development and function. Horm. Behav. 2011, 59, 364–368.
50. Ho, K.L.; McNae, I.W.; Schmiedeberg, L.; Klose, R.J.; Bird, A.P.; Walkinshaw, M.D. MeCP2 binding to DNA depends upon hydration at methyl-CpG. Mol. Cell 2008, 29, 525–531.
51. Klose, R.J.; Sarraf, S.A.; Schmiedeberg, L.; McDermott, S.M.; Stancheva, I.; Bird, A.P. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol. Cell 2005, 19, 667–678.
52. Jones, P.L.; Jan Veenstra, G.C.; Wade, P.A.; Vermaak, D.; Kass, S.U.; Landsberger, N.; Strouboulis, J.; Wolffe, A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 1998, 19, 187–191.
53. Nan, X.; Campoy, F.J.; Bird, A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88, 471–481.
54. Nikitina, T.; Shi, X.; Ghosh, R.P.; Horowitz-Scherer, R.A.; Hansen, J.C.; Woodcock, C.L. Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin. Mol. Cell. Biol. 2007, 27, 864–877.
55. Nan, X.; Hou, J.; Maclean, A.; Nasir, J.; Lafuente, M.J.; Shu, X.; Kriaucionis, S.; Bird, A. Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc. Natl. Acad. Sci. USA 2007, 104, 2709–2714.
56. Kimura, H.; Shiota, K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J. Biol. Chem. 2003, 278, 4806–4812.
57. Fuks, F.; Hurd, P.J.; Wolf, D.; Nan, X.; Bird, A.P.; Kouzarides, T. The Methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 2003, 278, 4035–4040.
58. Kokura, K.; Kaul, S.C.; Wadhwa, R.; Nomura, T.; Khan, M.M.; Shinagawa, T.; Yasukawa, T.; Colmenares, C.; Ishii, S. The ski protein family is required for MeCP2-mediated transcriptional repression. J. Biol. Chem. 2001, 276, 34115–34121.
59. Jeffery, L.; Nakielny, S. Components of the DNA methylation system of chromatin control are RNA-binding proteins. J. Biol. Chem. 2004, 279, 49479–49487.
60. Skene, P.J.; Illingworth, R.S.; Webb, S.; Kerr, A.R.W.; James, K.D.; Turner, D.J.; Andrews, R.; Bird, A.P. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 2010, 37, 457–468.
61. Georgel, P.T.; Horowitz-Scherer, R.A.; Adkins, N.; Woodcock, C.L.; Wade, P.A.; Hansen, J.C. Chromatin compaction by human MeCP2 assembly of novel secondary chromatin structures in the absence of DNA methylation. J. Biol. Chem. 2003, 278, 32181–32188.
62. Yasui, D.H.; Peddada, S.; Bieda, M.C.; Vallero, R.O.; Hogart, A.; Nagarajan, R.P.; Thatcher, K.N.; Farnham, P.J.; LaSalle, J.M. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc. Natl. Acad. Sci. USA 2007, 104, 19416–19421.
63. Harikrishnan, K.N.; Bayles, R.; Ciccotosto, G.D.; Maxwell, S.; Cappai, R.; Pelka, G.J.; Tam, P.P.L.; Christodoulou, J.; El-Osta, A. Alleviating transcriptional inhibition of the norepinephrine Slc6a2 transporter gene in depolarized neurons. J. Neurosci. 2010, 30, 1494–1501.
64. Kernohan, K.D.; Jiang, Y.; Tremblay, D.C.; Bonvissuto, A.C.; Eubanks, J.H.; Mann, M.R.W.; Bérubé, N.G. ATRX Partners with cohesin and MeCP2 and contributes to developmental silencing of imprinted genes in the brain. Dev. Cell 2010, 18, 191–202.
65. Tudor, M.; Akbarian, S.; Chen, R.Z.; Jaenisch, R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc. Natl. Acad. Sci. USA 2002, 99, 15536–15541.
66. Guy, J.; Cheval, H.; Selfridge, J.; Bird, A. The role of MeCP2 in the brain. Annu. Rev. Cell Dev. Biol. 2011, 27, 631–652.
67. Zachariah, R.M.; Rastegar, M. Linking epigenetics to human disease and Rett syndrome: The emerging novel and challenging concepts in MeCP2 research. Neural Plast. 2012, 2012, e415825.
68. Chahrour, M.; Jung, S.Y.; Shaw, C.; Zhou, X.; Wong, S.T.C.; Qin, J.; Zoghbi, H.Y. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320, 1224–1229.
69. Ben-Shachar, S.; Chahrour, M.; Thaller, C.; Shaw, C.A.; Zoghbi, H.Y. Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. Hum. Mol. Genet. 2009, 18, 2431–2442.
70. Jordan, C.; Francke, U. Ube3a expression is not altered in Mecp2 mutant mice. Hum. Mol. Genet. 2006, 15, 2210–2215.
71. Kriaucionis, S.; Paterson, A.; Curtis, J.; Guy, J.; MacLeod, N.; Bird, A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of rett syndrome. Mol. Cell. Biol. 2006, 26, 5033–5042.
72. Nuber, U.A.; Kriaucionis, S.; Roloff, T.C.; Guy, J.; Selfridge, J.; Steinhoff, C.; Schulz, R.; Lipkowitz, B.; Ropers, H.H.; Holmes, M.C.; et al. Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Hum. Mol. Genet. 2005, 14, 2247–2256.
73. Lang, F.; Strutz-Seebohm, N.; Seebohm, G.; Lang, U.E. Significance of SGK1 in the regulation of neuronal function. J. Physiol. 2010, 588, 3349–3354.
74. Storer, C.L.; Dickey, C.A.; Galigniana, M.D.; Rein, T.; Cox, M.B. FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol. Metab. 2011, 22, 481–490.
75. Murgatroyd, C.; Spengler, D. Epigenetic programming of the HPA axis: Early life decides. Stress 2011, 14, 581–589.
76. Wu, Y.; Patchev, A.V.; Daniel, G.; Almeida, O.F.X.; Spengler, D. Early-life stress reduces DNA methylation of the Pomc gene in male mice. Endocrinology 2014, 155, 1751–1762.
77. McGill, B.E.; Bundle, S.F.; Yaylaoglu, M.B.; Carson, J.P.; Thaller, C.; Zoghbi, H.Y. Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. USA 2006, 103, 18267–18272.
78. Müller, M.B.; Uhr, M.; Holsboer, F.; Keck, M.E. Hypothalamic-pituitary-adrenocortical system and mood disorders: Highlights from mutant mice. Neuroendocrinology 2004, 79, 1–12.
79. Zhou, Z.; Hong, E.J.; Cohen, S.; Zhao, W.; Ho, H.H.; Schmidt, L.; Chen, W.G.; Lin, Y.; Savner, E.; Griffith, E.C.; et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006, 52, 255–269.
80. Samaco, R.C.; Mandel-Brehm, C.; McGraw, C.M.; Shaw, C.A.; McGill, B.E.; Zoghbi, H.Y. Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome. Nat. Genet. 2012, 44, 206–211.
81. Ramocki, M.B.; Peters, S.U.; Tavyev, Y.J.; Zhang, F.; Carvalho, C.M.B.; Schaaf, C.P.; Richman, R.; Fang, P.; Glaze, D.G.; Lupski, J.R.; et al. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. Ann. Neurol. 2009, 66, 771–782.
82. Li, W.; Pozzo-Miller, L. BDNF deregulation in Rett syndrome. Neuropharmacology 2014, 76, 737–746.
83. Bellini, E.; Pavesi, G.; Barbiero, I.; Bergo, A.; Chandola, C.; Nawaz, M.S.; Rusconi, L.; Stefanelli, G.; Strollo, M.; Valente, M.M.; et al. MeCP2 post-translational modifications: A mechanism to control its involvement in synaptic plasticity and homeostasis? Front. Cell. Neurosci. 2014, 8, doi:10.3389/fncel.2014.00236.
84. Li, H.; Chang, Q. Regulation and function of stimulus-induced phosphorylation of MeCP2. Front. Biol. 2014, 9, 367–375.
85. Martinowich, K.; Hattori, D.; Wu, H.; Fouse, S.; He, F.; Hu, Y.; Fan, G.; Sun, Y.E. DNA methylation-related chromatin remodeling in activity-dependent Bdnf gene regulation. Science 2003, 302, 890–893.
86. Chen, W.G.; Chang, Q.; Lin, Y.; Meissner, A.; West, A.E.; Griffith, E.C.; Jaenisch, R.; Greenberg, M.E. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003, 302, 885–889.
87. Tao, J.; Hu, K.; Chang, Q.; Wu, H.; Sherman, N.E.; Martinowich, K.; Klose, R.J.; Schanen, C.; Jaenisch, R.; Wang, W.; et al. Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function. Proc. Natl. Acad. Sci. USA 2009, 106, 4882–4887.
88. Bracaglia, G.; Conca, B.; Bergo, A.; Rusconi, L.; Zhou, Z.; Greenberg, M.E.; Landsberger, N.; Soddu, S.; Kilstrup-Nielsen, C. Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis. EMBO Rep. 2009, 10, 1327–1333.
89. Gonzales, M.L.; Adams, S.; Dunaway, K.W.; LaSalle, J.M. Phosphorylation of distinct sites in MeCP2 modifies cofactor associations and the dynamics of transcriptional regulation. Mol. Cell. Biol. 2012, 32, 2894–2903.
90. Cohen, S.; Gabel, H.W.; Hemberg, M.; Hutchinson, A.N.; Sadacca, L.A.; Ebert, D.H.; Harmin, D.A.; Greenberg, R.S.; Verdine, V.K.; Zhou, Z.; et al. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron 2011, 72, 72–85.
91. Li, H.; Zhong, X.; Chau, K.F.; Williams, E.C.; Chang, Q. Loss of activity-induced phosphorylation of MeCP2 enhances synaptogenesis, LTP and spatial memory. Nat. Neurosci. 2011, 14, 1001–1008.
92. Nestler, E.J. Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2001, 2, 119–128.
93. Hyman, S.E.; Malenka, R.C.; Nestler, E.J. Neural mechanisms of addiction: The role of reward-related learning and memory. Annu. Rev. Neurosci. 2006, 29, 565–598.
94. Cassel, S.; Carouge, D.; Gensburger, C.; Anglard, P.; Burgun, C.; Dietrich, J.-B.; Aunis, D.; Zwiller, J. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol. Pharmacol. 2006, 70, 487–492.
95. Deng, J.V.; Rodriguiz, R.M.; Hutchinson, A.N.; Kim, I.-H.; Wetsel, W.C.; West, A.E. MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. Nat. Neurosci. 2010, 13, 1128–1136.
96. Mao, L.-M.; Horton, E.; Guo, M.-L.; Xue, B.; Jin, D.-Z.; Fibuch, E.E.; Wang, J.Q. Cocaine increases phosphorylation of MeCP2 in the rat striatum in vivo: A differential role of NMDA receptors. Neurochem. Int. 2011, 59, 610–617.
97. Deng, J.V.; Wan, Y.; Wang, X.; Cohen, S.; Wetsel, W.C.; Greenberg, M.E.; Kenny, P.J.; Calakos, N.; West, A.E. MeCP2 phosphorylation limits psychostimulant-induced behavioral and neuronal plasticity. J. Neurosci. 2014, 34, 4519–4527.
98. Hutchinson, A.N.; Deng, J.V.; Aryal, D.K.; Wetsel, W.C.; West, A.E. Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin. Neuropsychopharmacology 2012, 37, 321–337.
99. Schloesser, R.J.; Martinowich, K.; Manji, H.K. Mood-stabilizing drugs: Mechanisms of action. Trends Neurosci. 2012, 35, 36–46.
100. Hikosaka, O. The habenula: from stress evasion to value-based decision-making. Nat. Rev. Neurosci. 2010, 11, 503–513.
101. Green, J.; McLaughlin, K.A.; Berglund, P.A.; et al. Childhood adversities and adult psychiatric disorders in the national comorbidity survey replication i: Associations with first onset of DSM-IV disorders. Arch. Gen. Psychiatry 2010, 67, 113–123.
102. U.S. Department of Health and Human Services; Administration for Children and Families; Administration on Children, Youth and Families. Children’s Bureau Child. Maltreatment 2009. Available online: http://www.acf.hhs.gov/programs/cb/stats_research/index.htm#can (accessed on 2 December 2014).
103. U.S. Department of Health and Human Services; Administration for Children and Families; Administration on Children, Youth and Families; Children’s Bureau Child. Maltreatment 2010. Available online: http://www.acf.hhs.gov/programs/cb/stats_research/index.htm#can (accessed on 2 December 2014).
104. Briere, J.; Berliner, L.; Bulkley, J.A.; Jenny, C.; Reid, T. The APSAC Handbook on Child Maltreatment; American Professional Society on the Abuse of Children, Ed.; SAGE Publications: Thousand Oaks, CA, USA, 1996.
105. Olson, S. From Neurons to Neighborhoods: An Update: Workshop Summary; Institute of Medicine (U.S.), National Research Council (U.S.), Eds.; National Academies Press: Washington, DC, USA, 2012.
106. England, M.J.; Sim, L.J. Depression in Parents, Parenting, and Children: Opportunities to Improve Identification, Treatment, and Prevention; National Research Council (U.S.), Institute of Medicine (U.S.), Eds.; National Academies Press: Washington, DC, USA, 2009.
107. Edwards, V.J.; Holden, G.W.; Felitti, V.J.; Anda, R.F. Relationship between multiple forms of childhood maltreatment and adult mental health in community respondents: results from the adverse childhood experiences study. Am. J. Psychiatry 2003, 160, 1453–1460.
108. Felitti, V.J.; Anda, R.F.; Nordenberg, D.; Williamson, D.F.; Spitz, A.M.; Edward S.V.; Koss, M.P.; Marks, J.S. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The adverse childhood experiences (ACE) study. Am. J. Prev. Med. 1998, 14, 245–258.
109. Chapman, D.P.; Whitfield, C.L.; Felitti, V.J.; Dube, S.R.; Edwards, V.J.; Anda, R.F. Adverse childhood experiences and the risk of depressive disorders in adulthood. J. Affect. Disord. 2004, 82, 217–225.
110. Dube, S.R.; Anda, R.F.; Felitti, V.J.; Chapman, D.P.; Williamson, D.F.; Giles, W.H. Childhood abuse, household dysfunction, and the risk of attempted suicide throughout the life span: Findings from the adverse childhood experiences study. JAMA 2001, 286, 3089–3096.
111. Raabe, F.J.; Spengler, D. Epigenetic risk factors in PTSD and depression. Front. Mol. Psychiatry 2013, 4, 80.
112. Lupien, S.J.; McEwen, B.S.; Gunnar, M.R.; Heim, C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 2009, 10, 434–445.
113. McCrory, E.; De Brito, S.A.; Viding, E. Research Review: The neurobiology and genetics of maltreatment and adversity. J. Child. Psychol. Psychiatry 2010, 51, 1079–1095.
114. Lupien, S.J.; Fiocco, A.; Wan, N.; Maheu, F.; Lord, C.; Schramek, T.; Tu, M.T. Stress hormones and human memory function across the lifespan. Psychoneuroendocrinology 2005, 30, 225–242.
115. Hoffmann, A.; Spengler, D. The lasting legacy of social stress on the epigenome of the hypothalamic–pituitary–adrenal axis. Epigenomics 2012, 4, 431–444.
116. Patchev, A.V.; Rodrigues, A.J.; Sousa, N.; Spengler, D.; Almeida, O.F.X. The future is now: early life events preset adult behaviour. Acta. Physiol. 2014, 210, 46–57.
117. Fink, G. Encyclopedia of Stress, 2nd ed.; Academic Press: Waltham, MA, USA, 2007.
118. Murgatroyd, C.; Patchev, A.V.; Wu, Y.; Micale, V.; Bockmühl, Y.; Fischer, D.; Holsboer, F.; Wotjak, C.T.; Almeida, O.F.X.; Spengler, D. Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat. Neurosci. 2009, 12, 1559–1566.
119. Goncharova, N.D. Stress responsiveness of the hypothalamic-pituitary-adrenal axis: Age-related features of the vasopressinergic regulation. Front. Endocrinol. 2013, 4, doi:10.3389/fendo.2013.00026.
120. Makara, G.B.; Varga, J.; Barna, I.; Pintér, O.; Klausz, B.; Zelena, D. The vasopressin-deficient brattleboro rat: Lessons for the hypothalamo-pituitary-adrenal axis regulation. Cell. Mol. Neurobiol. 2012, 32, 759–766.
121. Schmidt, M.V.; Sterlemann, V.; Wagner, K.; Niederleitner, B.; Ganea, K.; Liebl, C.; Deussing, J.M.; Berger, S.; Schütz, G.; Holsboer, F.; et al. Postnatal glucocorticoid excess due to pituitary glucocorticoid receptor deficiency: Differential short- and long-term consequences. Endocrinology 2009, 150, 2709–2716.
122. Murgatroyd, C.; Spengler, D. Polycomb binding precedes early-life stress responsive DNA methylation at the avp enhancer. PLOS ONE 2014, 9, e90277.
123. Menger, Y.; Bettscheider, M.; Murgatroyd, C.; Spengler, D. Sex differences in brain epigenetics. Epigenomics 2010, 2, 807–821.
124. Chen, Y.; Bender, R.A.; Frotscher, M.; Baram, T.Z. Novel and transient populations of corticotropin-releasing hormone-expressing neurons in developing hippocampus suggest unique functional roles: A quantitative spatiotemporal analysis. J. Neurosci. 2001, 21, 7171–7181.
125. Chen, Y.; Andres, A.; Frotscher, M.; Baram, T.Z. Tuning synaptic transmission in the hippocampus by stress: the CRH system. Front. Cell. Neurosci. 2012, 6, 13.
126. Maras, P.M.; Baram, T.Z. Sculpting the hippocampus from within: stress, spines, and CRH. Trends Neurosci. 2012, 35, 315–324.
127. Wang, A.; Nie, W.; Li, H.; Hou, Y.; Yu, Z.; Fan, Q.; Sun, R. Epigenetic upregulation of corticotrophin-releasing hormone mediates postnatal maternal separation-induced memory deficiency. PLOS ONE 2014, 9, e94394.
128. Murat, B.; Devost, D.; Andrés, M.; Mion, J.; Boulay, V.; Corbani, M.; Zingg, H.H.; Guillon, G. V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH. Mol. Endocrinol. 2012, 26, 502–520.